Tardive Dyskinesia Therapeutics Market By Drug Class (Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors {Valbenazine, Deutetrabenazine}, Dopamine Receptor Blockers, GABA Receptor Modulators, Anticholinergics, Others), By Application (Antipsychotic-Induced Tardive Dyskinesia, Other Drug-Induced Tardive Dyskinesia, Idiopathic Tardive Dyskinesia ), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies), By End-User (Hospitals, Clinics, Specialty Treatment Centers, Homecare Settings), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Drug Class

• Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors
  • Valbenazine
  • Deutetrabenazine
• Dopamine Receptor Blockers
• GABA Receptor Modulators
• Anticholinergics
• Others

By Application

• Antipsychotic-Induced Tardive Dyskinesia
• Other Drug-Induced Tardive Dyskinesia
• Idiopathic Tardive Dyskinesia

 By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies

   By End-User

• Hospitals
• Clinics
• Specialty Treatment Centers
• Homecare Settings

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Neurocrine Biosciences
• Teva Pharmaceuticals
• AbbVie Inc.
• Johnson & Johnson
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Lundbeck A/S
• Dr. Reddy’s Laboratories
• Zydus Cadila
• Amneal Pharmaceuticals, Inc.
• Otsuka Pharmaceutical Co., Ltd.
• H. Lundbeck
• Takeda Pharmaceutical Company Limited
• Glenmark Pharmaceuticals
• Biogen Inc.